Our findings were comparable to previous economic evaluations on HCC surveillance for CHB in Australia in 2009, showing biannual ultrasound + AFP had an unfavourable ICER (> $400,000/QALY gained) against the current practice [50]. This evidence concerns the gene AFP and hepatocellular carcinoma.